데이터 상품 상세검색

[감염병특허]

감염병 특허의 권리자/명칭/초록 텍스트 데이터 (미국특허)

감염병 특허의 권리자/명칭/초록 텍스트 데이터

  • 등록일2022-12-07
  • 조회수2551
  • 다운로드498
  • 카테고리감염병특허
  • 17

데이터 기본 이용료

  • 무료
상세정보
데이터등록일 데이터 수정일 데이터 이용기한 판매제공처
2022-12-07 2023-07-25 무기한 BLT
데이터 제공포맷 데이터 제공방식 데이터 파일용량 데이터 상품구분
csv/zip 다운로드 162.81 MB dataset

■ 데이터상품설명 ICD 질병분류코드에 정의된 감염질환을 기준으로 질병별로 정리된 특허데이터를 가공해 제공합니다. 본 데이터 상품은 원문에 가까운 데이터의 제공이 목적이며, 질병/특허번호/날짜/권리자/명칭/초록 등의 정보가 수록되어있습니다. ■ 간략 통계 수록 감염병: 약 600종 (정의된 감염질환 1200여개에 대해 모두 스크리닝) 수록 특허수: 약 4만건 (2023년 02월 현재기준) 질병당 특허수 :평균 222건 (최소1 최대 6977건) ■ 데이터 내용설명 아래와 같은 데이터를 포함하고 있습니다 1) 질병정보 (질병ID/질병코드/질병명) 2) 특허번호정보 (특허ID/출원번호/등록번호) 3) 특허날짜정보 (출원일자/등록일자) 4) 특허권리자 5) 특허원문 (발명의명칭/초록) ■ 참고: ICD10 질병분류코드 코로나바이러스감염증-19 [U07.1] 콜레라 [A00] 결핵 [A15-A19] 디프테리아 [A36] 패혈증 [A40-41] 크로이츠펠트-야콥병 [A81.0] 바이러스수막염 [A87] 지카 바이러스 질환 [A92.5] 황열 [A95] 뎅기 [A97] 에볼라바이러스병 [A98.4] 헤르페스바이러스[단순헤르페스] 감염 [B00] 대상포진 [B02] 바이러스간염 [B15-B19] 인체면역결핍바이러스병 [B20-B24] 감염성 단핵구증 [B27] 백선증 [B35] 칸디다증 [B37] 샤가스병 [B57] 연충증 [B65-B83] 메티실린 내성 황색포도상구균 [U82.1]

샘플정보
컨텐츠ID
컨텐츠영어명
컨텐츠한국어명
컨텐츠대분류명
질병분류코드
MESH분류코드
국가코드
특허ID
특허출원번호
특허공개번호
특허등록번호
특허출원일자
특허출원공개일자
특허등록일자
특허최초공보발행일자
현재특허권리자그룹
특허발명의명칭제목
특허초록
메인CPC특허분류코드
전체CPC특허분류코드목록
CPC특허분류코드개수
메인IPC특허분류코드
전체IPC특허분류코드목록
IPC특허분류코드개수
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US00010160778B2 15/522692 20170334937 10160778 20151027 20171123 20181225 20171123 Concert Pharmaceuticals Pyrimidine phosphonic acid esters This invention relates to compounds of Formula (I): C07F9/6512 C07F9/6512|A61K31/675|A61P31/20 3 C07F9/6512 C07F9/6512|A61K31/675 2
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US20060239970A1 10/543216 20060239970 20040123 20061026 20061026 University of Rochester Herpesvirus amplicon particles The invention includes methods for delivering therapeutic agents to a patient through administration of herpesvirus amplicon particles generated by a cell that stably express herpes simplex virus (HSV) immediate early 3 (IE3) gene. C12N15/86 C12N15/86|A61K48/0091|C12N2710/16643|A61K48/00 4 A61K48/00 A61K48/00|C12N15/86 2
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US20080241127A1 11/955595 20080241127 20071213 20081002 20081002 Dyax Methods of Making Passive Immunotherapies Methods for isolating antibodies useful as passive immunotherapies are described. G01N33/6854 G01N33/6854|Y02A50/30|C07K16/08 3 A61K39/395 A61K39/395|C40B30/04 2
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US20090004744A1 12/113169 20090004744 20080430 20090101 20090101 Vaxiion Therapeutics MINICELLS AS VACCINES The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject. C12N15/74 C12N15/74|Y02A50/30|A61K2039/522|A61K39/02 4 C12N15/75 C12N15/75|C12N15/74 2
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US20110065753A1 12/873705 20110065753 20100901 20110317 20110317 Unither Virology METHODS OF TREATING POXVIRAL INFECTIONS Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Poxyiridae family using iminosugars, such as DNJ derivatives. A61K31/445 A61K31/445|A61P31/20|A61P31/12|A61K31/452|C07D211/46 5 A61K31/445 A61K31/445|C12N5/02|A61P31/20 3
941042 Rubella with other complications 기타 합병증을 동반한 풍진 피부 및 점막병변이 특징인 바이러스감염 B06.8 US US00006369068B1 09/319859 6369068 19990611 20020409 20020409 GlaxoSmithKline (GSK) Amino substituted pyrimidine containing compounds <p>Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.</p> C07D401/14 C07D401/14|C07D405/14|C07D403/04|C07D405/12|C07D409/14|C07D401/12 6 A61K31/506 A61K31/506|C07D401/14|C07D403/04|C07D401/12|C07D405/14|C07D405/12|C07D409/14 7
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US20140363523A1 14/372650 20140363523 20130117 20141211 20141211 Concert Pharmaceuticals DEUTERATED ALPHA-LIPOIC ACID The present invention provides a compound of Formula (I), wherein: each X is independently hydrogen or deuterium; and at least one X is deuterium. C07D339/04 C07D339/04|A61P3/04|A61P3/00|A61K45/06|A61K31/385 5 C07D339/04 C07D339/04|A61K45/06|A61K31/385 3
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US20150111899A1 14/580335 20150111899 20141223 20150423 20150423 InterMune PIRFENIDONE THERAPY AND INDUCERS OF CYTOCHROME P450 The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. A61K31/4418 A61K31/4418|Y02A50/30|A61K31/496|A61K31/4412 4 A61K31/4412 A61K31/4412|A61K31/496 2
211710 Viral infections characterized by skin and mucous membrane lesions 피부 및 점막병변이 특징인 바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B00-B09 US US20170071991A1 15/310556 20170071991 20150507 20170316 20170316 Virttu Biologics Oncolytic Virus and Aurora Kinase Inhibitor for the Treatment of Cancer The use of an oncolytic virus and an aurora kinase inhibitor in the treatment of cancer is disclosed. A61K35/763 A61K35/763|A61P35/00|A61K45/06|C12N2710/16632|A61K31/55|C12N7/00|A61P43/00 7 A61K31/55 A61K31/55|C12N7/00 2
211712 Varicella [chickenpox] 수두 피부 및 점막병변이 특징인 바이러스감염 B01 US US20140094383A1 14/044631 20140094383 20131002 20140403 20140403 The Ohio State University Tethered Lipoplex nanoparticle Biochips And Methods Of Use Disclosed are compositions and methods for the use of lipoplex nanoparticle chips and arrays in the detection of/diagnosis of a disease or condition. G01N33/56983 G01N33/56983|Y02A50/30|G01N33/5432 3 G01N33/569 G01N33/569 1
211713 Zoster [herpes zoster] 대상포진 피부 및 점막병변이 특징인 바이러스감염 B02 US US20090270427A1 12/433388 20090270427 20090430 20091029 20091029 Cancer Research Technology PURINE DERIVATIVES The present invention relates to compounds of formula 1 C07D473/16 C07D473/16|A61P31/20|A61P25/28|A61P43/00|A61P11/00|A61P31/18|A61P25/00|A61P35/02|A61P9/00|A61P31/14|A61P17/14|A61P35/00|A61P3/10|A61P31/12|A61P17/06|A61P31/22|A61P29/00|A61P13/12 18 A61K31/52 A61K31/52|C07D473/16|C12N9/99|A61P35/00 4
211713 Zoster [herpes zoster] 대상포진 피부 및 점막병변이 특징인 바이러스감염 B02 US US20190256899A1 16/134497 20190256899 20180918 20190822 20190822 Accugenomics NUCLEIC ACID AMPLIFICATION AND USE THEREOF The invention features compositions and methods that are useful for the measurement of the quantity of a nucleic acid target in a sample. C12Q1/6832 C12Q1/6832|C12Q2600/158|C12Q1/686|C12Q2600/156|C12Q1/701|C12Q1/689|C12Q1/6886 7 C12Q1/6832 C12Q1/6832|C12Q1/689|C12Q1/6886|C12Q1/70|C12Q1/686 5
211716 Measles 홍역 피부 및 점막병변이 특징인 바이러스감염 B05 US US20120029015A1 13/258654 20120029015 20100323 20120202 20120202 Marciniak Andrzej|Turski Waldemar Novel medical use of kynurenic acid, its precursors and derivatives The invention relates to the use of kynurenic acid derivatives of general formula (I), A61K31/47 A61K31/47|Y02A50/30|A61P5/48|A61P1/18 4 A61K31/47 A61K31/47|A61P1/18|C07D215/48 3
211717 Rubella [German measles] 풍진 피부 및 점막병변이 특징인 바이러스감염 B06 US US00006562832B1 09/446036 6562832 19991215 20030513 20030513 GlaxoSmithKline (GSK) Substituted imidazole compounds <p>Novel 1,4,5-subsituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.</p> C07D403/04 C07D403/04|C12Q1/6827 2 C07D233/54 C07D233/54|C07D403/04|C12Q1/68 3
211717 Rubella [German measles] 풍진 피부 및 점막병변이 특징인 바이러스감염 B06 US US20050075352A1 10/884788 20050075352 20040702 20050407 20050407 GlaxoSmithKline (GSK) 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors Novel substituted quinazoline compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors. C07D401/06 C07D401/06|C07D239/80 2 A61K31/517 A61K31/517 1
941043 Rubella arthritis 풍진 관절염 피부 및 점막병변이 특징인 바이러스감염 B06.8.0 US US00005929076B 09/101525 5929076 19981029 19990727 19990727 GlaxoSmithKline (GSK) Cycloalkyl substituted imidazoles <p>Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy.</p> C07D403/04 C07D403/04 1 A61K31/505 A61K31/505|C07D403/04 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008637663B2 12/441812 20100022578 8637663 20071116 20100128 20140128 20100128 Janssen Sciences Ireland UC Macrocyclic inhibitors of hepatitis C virus Inhibitors of HCV replication of formula (I) C07D491/056 C07D491/056|C07D401/12|A61P31/14|A61P1/16|A61K31/427|Y02A50/30|C07D491/04|A61P43/00|A61P31/12|A61K31/4741|C07D491/048 11 C07D225/04 C07D225/04|A61K31/4709|A61P31/12|A61K31/4741|C07D245/04 5
941051 Vaccinia 우두 피부 및 점막병변이 특징인 바이러스감염 B08.0.3 US US00006177076B1 09/206425 6177076 19981207 20010123 20010123 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus <p>Methods of treating bladder cancer in a patient by administration of wildtype vaccinia virus are provided.</p> A61K9/0034 A61K9/0034|A61K39/285|A61K39/12|C12N2710/24132|A61P35/00 5 A61P35/00 A61P35/00|A61K39/285|A61K9/00|A61K35/76 4
941047 Other orthopoxvirus infections 기타 오르토폭스바이러스감염 피부 및 점막병변이 특징인 바이러스감염 B08.0 US US20130302367A1 13/880814 20130302367 20111021 20131114 20131114 Hokkaido University VIRUS VECTOR FOR PRIME/BOOST VACCINES, WHICH COMPRISES VACCINIA VIRUS VECTOR AND SENDAI VIRUS VECTOR [Problem] A61K39/39 A61K39/39|C12N2740/16134|C12N15/86|C12N2740/16034|A61K39/21|C12N2710/24143|A61K39/12|Y02A50/30|A61K2039/545|C12N2760/18843|A61K2039/53 11 A61K39/39 A61K39/39 1
941053 Exanthema subitum [sixth disease] 돌발발진[제6병] 피부 및 점막병변이 특징인 바이러스감염 B08.2 US US20090227637A1 12/097350 20090227637 20061206 20090910 20090910 Bayer Healthcare DIARYL UREAS FOR TREATING VIRUS INFECTIONS The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound. A61K31/44 A61K31/44|A61P31/12 2 A61K31/44 A61K31/44|A61P31/12 2
941061 Foot-and-mouth disease 족구병 피부 및 점막병변이 특징인 바이러스감염 B08.8.1 US US20060222662A1 10/546031 20060222662 20040217 20061005 20061005 responsif Composition to be administered to a living being and method for marking agents The invention relates to compositions to be administered to a living being, a method for marking agents that are administered to living beings, the use thereof, and an accelerated test. C07K14/005 C07K14/005|A61K47/6901|A61K47/646|C12N2770/22022|A61K2039/5258|A61K39/00 6 A61K39/12 A61K39/12|A61K38/10|A61K38/08 3
941061 Foot-and-mouth disease 족구병 피부 및 점막병변이 특징인 바이러스감염 B08.8.1 US US20080194504A1 10/588414 20080194504 20050204 20080814 20080814 Advanced Bionutrition Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals The invention is directed to compositions (e.g., feeds, feed supplements, and therapeutic products) and methods for inhibiting an animal pathogen using RNA-interference technology. C12N15/111 C12N15/111|C12N2310/53|A61P31/10|C12N2310/14|A61P31/04|C12N2310/111|C12N15/1131|C12N2320/32|A61P31/12 9 A61K31/7105 A61K31/7105|A61P31/04|A61P31/10|A61P31/12 4
941061 Foot-and-mouth disease 족구병 피부 및 점막병변이 특징인 바이러스감염 B08.8.1 US US20160130565A1 14/935061 20160130565 20151106 20160512 20160512 Princeton University Method to Produce Virus in Cultured Cells A method for improving virus production in a host cell infected with the virus is provided. C12N7/00 C12N7/00|C12N2710/16751|C12N2710/16151 3 C12N7/00 C12N7/00 1
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00005427909B 07/940242 5427909 19920908 19950627 19950627 Immuno Oligonucleotides and determination system of HCV genotypes <p>Hepatitis C virus oligonucleotides and a system to determine hepatitis C virus genotypes with polymerase chain reaction utilizing those oligonucleotides as primers.</p> C12Q1/707 C12Q1/707 1 C12P19/34 C12P19/34|C12Q1/70|C12Q1/68|C07H21/04 4
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00005633388B 08/625717 5633388 19960329 19970527 19970527 Wyeth Compounds, compositions and methods for treatment of hepatitis C <p>Heterocyclic substituted carboxamides are useful in prophylaxis and treatment of hepatitis C virus infections.</p> C07D235/20 C07D235/20|C07D235/18 2 C07D403/12 C07D403/12|A61K31/415|C07D235/18|C07D235/20 4
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00005759795B 08/612987 5759795 19960308 19980602 19980602 MSD (Merck & Company) Assay for determining inhibitors of ATPase <p>This invention provides materials and methods for identifying inhibitors of a Hepatitis C Virus NS3 protein ATPase. Methods for making and purifying such an ATPase are also provided by this invention.</p> C12Q1/66 C12Q1/66|C12Q1/42 2 C12Q1/42 C12Q1/42|C12Q1/66 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00005780219B 08/371583 5780219 19950112 19980714 19980714 Biolucent|Cytyc|Cytyc Surgical Products|Direct Radiography|Gen-Probe|Gen-Probe Prodesse|Hologic|Suros Surgical Systems|Third Wave Technologies Nucleic acid amplification oligonucleotides and probes to human hepatitis B virus <p>Amplification oligonucleotides and hybridization assay probes specific for Human Hepatitis B Virus.</p> C12Q1/706 C12Q1/706 1 C07H21/04 C07H21/04|C12Q1/68|C12Q1/70 3
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00005830905B 08/625718 5830905 19960329 19981103 19981103 Wyeth Compounds, compositions and methods for treatment of hepatitis C <p>Derivatives of piperidine are useful in prophylaxis and treatment of hepatitis C virus infections.</p> C07D401/14 C07D401/14|C07D211/62|C07D211/58 3 C07D401/06 C07D401/06|A61K31/445|C07D401/14|C07D211/62|C07D211/58 5
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00005939423B 08/834378 5939423 19970416 19990817 19990817 Sciclone Pharmaceuticals Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir <p>Treatment of hepatitis B virus (HBV) infection in a patient by administering to the patient a drug regimen including an antiviral- effective amount of thymosin alpha 1 (T&agr;1) and an antiviral- effective amount of famciclovir.</p> A61K31/52 A61K31/52|A61K38/2292 2 A61K31/52 A61K31/52|A61K38/22 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00006017756B 08/193627 6017756 19940207 20000125 20000125 Wilderness Place Holdings Method and reagent for inhibiting hepatitis B virus replication <p>An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis B virus.</p> C12N15/1131 C12N15/1131|A61P31/14|C12N2310/121|A61K38/00|C12Q1/6876 5 A61P31/14 A61P31/14|C12Q1/68|C12N15/113|A61K38/00 4
968871 hepatitis C C형간염 바이러스간염 B17.1|B18.2 US US20050152875A1 11/046296 20050152875 20050128 20050714 20050714 Toray Industries Preventives for reinfection after liver transplantation Reinfection with the hepatitis C virus after liver transplantation is protected by administering IFN-β before liver transplantation, and thus IFN-β is useful as a reinfection protecting agent. A61K38/215 A61K38/215|A61P31/14|A61P31/00|A61P1/16|A61P1/00 5 A61K38/21 A61K38/21 1
968871 hepatitis C C형간염 바이러스간염 B17.1|B18.2 US US20140206017A1 14/122984 20140206017 20120601 20140724 20140724 Gilead Sciences LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF The present disclosure provides an assay to detect and/or quantify circulating lysyl oxidase-like 2 (LOXL2) poly-peptides in an individual. The assay is useful in diagnostic and prognostic applications, which are also provided. G01N33/573 G01N33/573|A61K2039/505|C07K16/40 3 G01N33/573 G01N33/573 1
211726 Human immunodeficiency virus [HIV] disease 인체면역결핍바이러스병 인체면역결핍바이러스병 B20-B24 US US00007569723B2 12/014185 20080114068 7569723 20080115 20080515 20090804 20080515 Boehringer Ingelheim International Benzoic acid derivatives as non nucleoside reverse-transcriptase inhibitors Compounds of formula (I): C07C235/68 C07C235/68|A61P31/18|C07C255/56|C07C235/24 4 C07C229/08 C07C229/08|A61K31/195|A61P31/18|C07C229/02 4
968871 hepatitis C C형간염 바이러스간염 B17.1|B18.2 US US20160031927A1 14/772818 20160031927 20140219 20160204 20160204 Alexandre Vasilievich Ivachtchenko|Asavi Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof Compounds of the general formula 1, stereoisomers, pharmaceutically acceptable salts, and/or hydrates, solvates or crystalline forms thereof C07H19/10 C07H19/10|A61P31/12|C07F9/65586|A61P43/00|A61P31/16|A61P31/14 6 C07H19/10 C07H19/10 1
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00006964771B1 08/923783 6964771 19970904 20051115 20051115 Quadrant Drug Delivery Method for stably incorporating substances within dry, foamed glass matrices The invention provides methods for producing foamed glass and the compositions obtained thereby. The compositions are suitable for stable storage of a wide variety of substances, particularly biological and pharmaceutical. C12N1/04 C12N1/04|A61K9/2095|A61K9/2018|Y02A50/30 4 A61K9/14 A61K9/14|A61K9/20|A61K9/00|A61K47/00|C12N1/04 5
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00007022688B1 08/985667 7022688 19971205 20060404 20060404 Wyeth Use of 17&#946;-dihydroequilenin as an antioxidant This invention provides a method of using 17β-dihydroequilenin or a pharmaceutically acceptable salt of 17β-dihydroequilenin-3-sulfate ester as an antioxidant. A61K31/56 A61K31/56 1 A61K31/56 A61K31/56 1
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00007473688B2 11/516435 20070078122 7473688 20060906 20070405 20090106 20070405 Bristol-Myers Squibb Indolobenzazepine HCV NS5B inhibitors The invention encompasses compounds and salts of Formulas I, II, III, and IV as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. C07D491/14 C07D491/14|A61P31/14|A61P31/00|C07D487/04 4 A61K31/55 A61K31/55|A61P31/00|C07D487/04|C07D223/14 4
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00007135462B2 10/992548 20050267040 7135462 20041118 20051201 20061114 20051201 Bristol-Myers Squibb Hepatitis C virus inhibitors Hepatitis C virus inhibitors are disclosed having the general formula: A61K31/40 A61K31/40|A61P43/00|A61P31/12|C07K5/0827|A61K38/00|C07K5/0808|A61P1/16|A61K31/4709|A61P31/14 9 A61K38/00 A61K38/00|A61K38/05|C07K5/083|C07K5/08|A61K31/695|A61K38/06|A61K31/4709|A61K38/21|A61K31/40|C07K5/06 10
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00007173004B2 10/825693 20050090432 7173004 20040416 20050428 20070206 20050428 Bristol-Myers Squibb Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus A compound of formula I: C07K5/0804 C07K5/0804|C12P41/005|A61K38/00|C12P13/04|A61P1/16|A61P31/14|A61P43/00|C12P7/62|A61P31/22 9 A61K38/00 A61K38/00|C07K5/12|C12P41/00|C07K5/083|C07K7/00|C12P13/04|A61K38/12|C07K|C12P7/62 9
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00009624183B2 14/798879 20150315165 9624183 20150714 20151105 20170418 20151105 Gilead Sciences Process for the preparation of a fluorolacton derivative A novel process for the preparation of a fluorolactone derivative of the formula C07D263/26 C07D263/26|A61P31/14|Y02P20/55|C07D413/06|C07D307/33 5 C07D307/33 C07D307/33|C07D263/26|C07D413/06 3
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008193346B2 12/328380 20090156800 8193346 20081204 20090618 20120605 20090618 Enanta Pharmaceuticals Process for making macrocyclic oximyl hepatitis C protease inhibitors The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds. C07D487/04 C07D487/04|C07D519/00|C07K5/081|C07K5/0804|C07K5/0802 5 C07D245/02 C07D245/02|C07K5/12|C07K5/08 3
211731 Mumps 볼거리 기타 바이러스질환 B26 US US20190218524A1 16/366278 20190218524 20190327 20190718 20190718 Princeton University Method to Produce Virus in Cultured Cells Supplemented With Alpha-Ketoglutarate A method is provided to improve virus production is an infected host cell by culturing the infected cell in an effective amount of alpha-ketoglutarate. C12N7/00 C12N7/00|C12N2710/16151|C12N2501/999|C12N2500/36|C12N5/0018|C12N2710/16751 6 C12N7/00 C12N7/00|C12N5/00 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00007425552B2 11/304902 20060189602 7425552 20051216 20060824 20080916 20060824 Anadys Pharmaceuticals Pyridazinone compounds The invention is directed to pyridazinone compounds of Formula I and pharmaceutical compositions containing compounds of Formula I C07D417/04 C07D417/04|C07D513/04|C07D417/14|A61P31/14|A61P31/12 5 C07D513/04 C07D513/04|A61K31/549|C07D417/04|C07D498/02 4
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00007476499B2 11/762607 20080090225 7476499 20070613 20080417 20090113 20080417 The Leland Stanford Junior University Methods of identifying anti-viral agents The present invention provides methods of identifying candidate anti-viral agents. C12Q1/18 C12Q1/18 1 C12Q1/70 C12Q1/70|C12Q1/18 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00007501433B2 11/104281 20050261329 7501433 20050412 20051124 20090310 20051124 Taiwanj Pharmaceuticals Opioid and opioid-like compounds and uses thereof The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage. C07D221/28 C07D221/28|C07D489/08|C07D489/02|C07D489/00|A61K31/485 5 A61K31/485 A61K31/485|C07D489/00|C07D489/08|C07D221/28|C07D519/00|C07D489/02 6
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US20030009775A1 10/157099 20030009775 20020528 20030109 20030109 The Leland Stanford Junior University Mouse model for hepatitis C <p>A rodent model for HCV infection is obtained by introducing into rodents which harbor a liver-specific defect an expression system which comprises an HCV replicon or a reverse transcript thereof and at least a nucleotide sequence encoding a rescue protein which remedies the defect. </p> A01K67/027 A01K67/027 1 A01K67/027 A01K67/027 1
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008183277B2 11/995560 20080262058 8183277 20060728 20081023 20120522 20081023 Janssen Sciences Ireland UC Macrocylic inhibitors of hepatitis C virus Inhibitors of HCV replication of formula (I) C07D487/04 C07D487/04|A61P31/14|A61P31/00|C07D403/04|A61P43/00|A61P31/12 6 A61K31/407 A61K31/407|C07D487/04|A61P31/12|A61K31/41 4
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00010603299B2 16/502150 20190380995 10603299 20190703 20191219 20200331 20191219 Steven Baranowitz Prevention and treatment of viral infections The present disclosure targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies. A61K31/343 A61K31/343|Y02A50/30|A61P31/14 3 A61K31/24 A61K31/24|A61K31/343|A61P31/14|A61K31/34|A61K31/65 5
968871 hepatitis C C형간염 바이러스간염 B17.1|B18.2 US US20120142605A1 13/319004 20120142605 20100505 20120607 20120607 Amgen METHODS OF TREATING PSORIASIS The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid. A61K31/57 A61K31/57|A61P17/06|A61K38/191 3 A61K38/16 A61K38/16|A61P17/06 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008198045B2 12/297488 20090311744 8198045 20070419 20091217 20120612 20091217 Ratiopharm Expression of O-glycosylated therapeutic proteins in prokaryotic microorganisms The invention relates to methods of producing an O-glycosylated soluble therapeutic protein in a prokaryotic microorganism by co-expressing the therapeutic protein and a heterologous glycosyltransferase that transfers a sugar moiety to an amino acid acceptor on the therapeutic protein. C12P21/005 C12P21/005|A61P43/00 2 C12P21/06 C12P21/06|C07H21/04|C12N1/20|C12N1/21|C12N15/00|C12N9/10|C12P19/04 7
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008377994B2 12/299997 20090306224 8377994 20060510 20091210 20130219 20091210 Evonik Degussa Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions The use of Sch?lpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described. A61K9/1611 A61K9/1611|A61K9/1694 2 A61K47/00 A61K47/00|A61K31/19|A61K47/02|A61K9/20 4
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008426360B2 12/269941 20090149491 8426360 20081113 20090611 20130423 20090611 Enanta Pharmaceuticals Carbocyclic oxime hepatitis C virus serine protease inhibitors The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: C07D471/04 C07D471/04|C07D225/04|C07D409/12|C07D405/12|C07D245/04|C07D401/12 6 A61K31/4709 A61K31/4709|A61K31/4375|A61K38/00|C07D215/00|C07D245/02|C07D471/12 6
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00009134228B2 14/402849 20150129766 9134228 20130521 20150514 20150915 20150514 GSK (GLaxoSmithKline) Biologicals Method for determining a concentration of a polysorbate species in a mixture The present invention relates to a method of measuring polysorbates, such as polysorbate 80, using Attenuated Total Reflectance-Fourier Transform Infrared spectroscopy (ATR-FTIR). G01N21/3577 G01N21/3577|G01N2021/3595|G01J3/28|G01N21/552|G01N21/55 5 G01J5/02 G01J5/02|G01N21/35|G01N21/55|G01J3/28 4
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008486384B2 12/446487 20100303761 8486384 20071029 20101202 20130716 20101202 LIVACTUS Lipidized interferon and methods of treating viral hepatitis The present invention is directed to methods and compositions useful in increasing in mammals the absorption and retention of polypeptides. The invention provides lipid-conjugated interferon having increased liver uptake and increased plasma half-life. A61K38/21 A61K38/21|A61P1/16|A61K47/543|A61P31/14|A61P31/12 5 A61K38/21 A61K38/21|A61P1/16|A61P31/14|C07K14/56|A61K38/00 5
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008530182B2 12/746649 20110201039 8530182 20081205 20110818 20130910 20110818 Centers for Disease Control and Prevention Viral protein quantification process and vaccine quality control therewith A process of quantifying proteins in a complex mixture is provided. The invention has utility in quantifying proteins in a complex preparation of uni- or multivalent commercial or research vaccine preparations. G01N30/7233 G01N30/7233|G01N2030/045|G01N2030/8831|G01N2030/8868 4 C12Q1/37 C12Q1/37 1
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008709999B2 13/260334 20120028978 8709999 20100326 20120202 20140429 20120202 Presidio Pharmaceuticals Substituted bicyclic HCV inhibitors Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C. C07D403/14 C07D403/14|C07D409/14|C07D417/14|A61P31/14|C07D413/14|C07D405/14 6 A61K38/00 A61K38/00|A01N37/18|C07D405/14|A61K31/4164|A61P31/14|A61K31/427|C07D401/14|C07D403/14|A61K31/454|C07D417/14|A61K31/5377|C07D413/14 12
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008754105B2 13/109395 20110237621 8754105 20110517 20110929 20140617 20110929 Janssen Sciences Ireland UC Macrocyclic inhibitors of hepatitis C virus Inhibitors of HCV replication of formula (I) C07D487/04 C07D487/04|A61P31/14|A61P31/12|C07D413/12|A61P43/00 5 A01N43/42 A01N43/42|A61K31/47|A61K31/4725|C07D498/04|A61K31/4709|A61P31/14|C07D401/12 7
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00008911934B2 12/739648 20100311038 8911934 20081031 20101209 20141216 20101209 Debiopharm|Katholieke Universiteit Leuven (Ku Leuven) Near full-genome assay of HCV drug resistance The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs. C12Q1/707 C12Q1/707 1 C12Q1/70 C12Q1/70|C07H21/00 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00009212168B2 13/667197 20130115194 9212168 20121102 20130509 20151215 20130509 Theravance Biopharma Hepatitis C virus inhibitors The invention provides compounds of formula (I): A61K31/496 A61K31/496|A61P31/14|A61P43/00|A61P31/12|C07D413/14|C07D491/113|C07D405/14|C07D409/14|C07D401/14|A61K45/06|A61P1/16|A61K31/5377|A61K31/541 13 C07D401/14 C07D401/14|C07D405/14|C07D409/14|C07D413/14|C07D491/113|A61P31/14|A61K31/541|A61K31/5377|C07F5/02|A61K31/7052|C07D417/14|A61K31/496|A61K31/7056|A61K38/21 14
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00009242983B2 14/247609 20140221382 9242983 20140408 20140807 20160126 20140807 Gerhard Puerstinger|Katholieke Universiteit Leuven (Ku Leuven) Viral inhibitors Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), C07D471/04 C07D471/04|A61P31/12|A61P31/00|A61P31/14 4 A61K31/4353 A61K31/4353|A61K31/437|C07D471/04 3
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00009527904B2 14/484842 20150010578 9527904 20140912 20150108 20161227 20150108 California Institute of Technology (CALTECH) Delivery of proteins using adeno-associated virus (AAV) vectors Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors. C07K16/109 C07K16/109|C12N7/00|C12N2750/14141|A61P31/12|A61P31/14|C07K16/1045|A61P31/18|A61P31/20|C12N2750/14143 9 A61K48/00 A61K48/00|A01K67/00|C12N7/00|C07K16/10|C07H21/04 5
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00009637485B2 14/926393 20160122344 9637485 20151029 20160505 20170502 20160505 F. Hoffmann-La Roche 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection The invention provides novel compounds having the general formula: C07D471/04 C07D471/04|A61P1/16|A61P31/20 3 A61K31/4985 A61K31/4985|C07D471/04 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00010034893B2 14/169387 20140219958 10034893 20140131 20140807 20180731 20140807 Enanta Pharmaceuticals 5, 6-D2 uridine nucleoside/tide derivatives In one aspect, the invention provides compounds represented by Formula I, A61K31/7072 A61K31/7072|C07H19/10|C07H19/11|A61K31/13|A61K31/7056|A61K38/21|A61K45/06|C07H19/06 8 C07H19/06 C07H19/06|C07H19/10|C07H19/11|A61K31/7072|A61K45/06|A61K31/13|A61K31/7056|A61K38/21 8
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00010160743B2 14/891895 20160115149 10160743 20140516 20160428 20181225 20160428 Janssen Sciences Ireland UC Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B Inhibitors of HBV replication of formula (I) C07D333/38 C07D333/38|A61P31/22|A61P31/12|C07D409/12|A61P43/00 5 C07D333/38 C07D333/38|C07D409/12 2
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US00010301268B2 15/263033 20170066724 10301268 20160912 20170309 20190528 20170309 The Salk Institute for Biological Studies Analogs of fexaramine and methods of making and using Novel compounds having a formula C07D231/56 C07D231/56|C07C2602/42|C07B59/002|C07B59/001|C07C2601/14|C07C233/63|C07B2200/05 7 C07D231/56 C07D231/56|C07C233/63|C07B59/00 3
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US20020037868A1 09/880945 20020037868 20010615 20020328 20020328 Institut Pasteur Method for detecting hepatitis C <p>The present invention provides methods of detecting hepatitis C virus. </p> G01N33/5767 G01N33/5767|C12N5/163|C07K16/109|G01N2333/186|C12Q1/707|C12Q1/686 6 C12Q1/70 C12Q1/70|G01N33/543|G01N33/53|G01N33/537|A61K31/70|C12P19/34|A01N43/04 7
968872 hepatitis D D형간염 바이러스간염 B16.0-1|B18.0 US US20090156473A1 12/325598 20090156473 20081201 20090618 20090618 Virologik PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL INFECTIONS AND/OR TUMOR DISEASES BY INHIBITING PROTEIN FOLDING AND PROTEIN BREAKDOWN The invention relates to the treatment of viral diseases with at least one proteasome inhibitor and one inhibitor of protein-folding enzymes. A61K31/00 A61K31/00|A61K31/325|Y02A50/30|A61P35/00|A61P31/12|A61K31/4965 6 A61K38/13 A61K38/13|A61K31/436|A61K38/00 3
211719 Viral hepatitis 바이러스간염 바이러스간염 B15-B19 US US20050208653A1 11/125577 20050208653 20050510 20050922 20050922 ES Cell International Method of isolating bile duct progenitor cells The present invention relates to a substantially pure population of viable bile duct progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny. A61K35/39 A61K35/39|C12N5/0678|A61K35/413|C12N2501/148|C12N5/0672|A61K35/407|C12N2501/115|A61P31/20|C12N2501/113|A61P31/04|C12N2501/11|A61P1/16 12 C12N5/08 C12N5/08|C12N5/06 2
211720 Acute hepatitis A 급성 A형간염 바이러스간염 B15 US US00008716262B2 12/645765 20110015146 8716262 20091223 20110120 20140506 20110120 Gilead Sciences Nucleoside phosphoramidates A nucleoside compound having activity against hepatitis C virus is disclosed. C07H19/20 C07H19/20|A61P31/12|A61P31/14|A61P31/16|A61P31/18|A61P31/20|A61P43/00|Y02A50/30 8 A01N43/04 A01N43/04|A61K31/70|C07H19/04|A61K31/7076|A61P31/16|A61P31/14|A61P31/20|C07H19/20 8
941087 HIV disease resulting in encephalopathy 뇌병증을 유발한 인체면역결핍바이러스병 인체면역결핍바이러스병 B22.0 US US20080188510A1 11/419816 20080188510 20060523 20080807 20080807 EISAI R&D Management NOVEL METHODS USING ZONISAMIDE The present invention relates to usefulness of zonisamide as a pharmaceutical composition for treating dementia or cognitive impairment. A61K31/423 A61K31/423|A61P25/00|A61K31/445|A61K31/4355 4 A61K31/423 A61K31/423|A61K31/4355|A61K31/445|A61P25/00 4
968871 hepatitis C C형간염 바이러스간염 B17.1|B18.2 US US20110112100A1 12/868342 20110112100 20100825 20110512 20110512 Pfizer Hepatitis C Virus Inhibitors The present invention relates to compounds of the formula (I) C07D403/14 C07D403/14|C07D403/04|C07D401/14|A61P31/14|C07F7/0812|C07F5/025 6 A61K31/498 A61K31/498|C07D241/36|A61P31/14 3
211720 Acute hepatitis A 급성 A형간염 바이러스간염 B15 US US20120202794A1 13/353538 20120202794 20120119 20120809 20120809 Gilead Pharmasset COMPOUNDS Disclosed herein are compounds useful for treating a viral infection, such as HCV. C07D241/08 C07D241/08|C07D261/12|C07D413/04|A61P31/12|C07D497/04|C07D409/04|C07D417/06|C07D405/06|C07D413/14|C07D403/06|C07D413/06 11 A61K31/551 A61K31/551|C07D417/06|A61K31/496|C07D241/04|A61P31/12|A61K31/495|C07D403/06|C07D405/06 8
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00010927116B2 15/999701 20190010155 10927116 20180820 20190110 20210223 20190110 F. Hoffmann-La Roche Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid The present invention relates to a process for synthesizing a compound of formula (I), C07D487/04 C07D487/04 1 C07D487/04 C07D487/04 1
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US20090099216A1 12/067781 20090099216 20060922 20090416 20090416 AstraZeneca NOVEL ADENINE COMPOUND A novel adenine compound represented by the formula (1): C07D473/18 C07D473/18|A61P11/02|A61P31/20|A61P29/00|A61P43/00|A61P31/18|A61P27/02|A61P37/08|A61P31/14|A61P17/00|A61P37/02|A61P31/12|A61P11/06|A61P35/00|A61P31/04 15 A61K31/522 A61K31/522|C07D473/18 2
968871 hepatitis C C형간염 바이러스간염 B17.1|B18.2 US US20060258738A1 11/433378 20060258738 20060512 20061116 20061116 Icahn School of Medicine At Mount Sinai (Ismms, Mount Sinai School of Medicine of New York University) Use of dronabinol for treatment of side effects of Hepatitis C therapy The present invention provides methods for treating and preventing the gastrointestinal side effects associated with anti-HCV therapy comprising administering delta-9-tetrahydrocannabinol. A61K38/21 A61K38/21|A61K31/7056|A61K31/353 3 A61K31/353 A61K31/353|A61K38/21|A61K31/7056 3
211726 Human immunodeficiency virus [HIV] disease 인체면역결핍바이러스병 인체면역결핍바이러스병 B20-B24 US US20070202515A1 11/549019 20070202515 20061012 20070830 20070830 Pathologica Promac signature application The present invention is directed to ProMac signature genes and methods and kits for using the ProMac signature genes for diagnostic, prognostic, or monitoring ProMac associated diseases. C12Q1/6883 C12Q1/6883|C12Q2600/106|B82Y30/00|B82Y15/00|C12Q2600/158|C12Q2600/118 6 C12Q1/68 C12Q1/68|C12M3/00 2
211725 Chronic viral hepatitis 만성 바이러스간염 바이러스간염 B18 US US00006280728B1 09/245820 6280728 19990205 20010828 20010828 Mucos Pharma Treatment of hepatitis C virus infection using a protease and a flavonoid <p>The use of at least one hydrolytic enzyme and at least one flavonoid shows better activity than &agr;-interferon or ribavirin in the treatment of diseases caused by hepatitis C viruses.</p> A61K38/4826 A61K38/4826|A61K38/4873 2 A61K38/48 A61K38/48 1
211725 Chronic viral hepatitis 만성 바이러스간염 바이러스간염 B18 US US00009611289B2 14/120366 20140371190 9611289 20140514 20141218 20170404 20141218 Intercept Pharmaceuticals Farnesoid X receptor modulators The present invention provides a compound of formula (I): A61K31/575 A61K31/575|A61P13/00|A61P43/00|A61P11/00|C07J71/001|C07J41/0061|C07J31/006|C07J9/005|A61P1/00|A61P1/16 10 A61K31/56 A61K31/56|C07J9/00|C07J41/00|C07J71/00|C07J31/00 5
211725 Chronic viral hepatitis 만성 바이러스간염 바이러스간염 B18 US US20050042226A1 10/875528 20050042226 20040625 20050224 20050224 Trillium Therapeutics Treatment of chronic human viral hepatitis The use of Fgl2 inhibitors to treat and control the progression of human Hepatitis B virus-induced hepatitis is described. Inhibitors of Fgl2 include antibodies to Fgl2. A01K67/0276 A01K67/0276|A01K2267/0337|C07K14/75|A01K2227/105|A61P31/20|A01K2217/075|C12N15/8509|A61K2039/505|C07K16/40 9 A61K39/42 A61K39/42|C12Q1/68 2
211725 Chronic viral hepatitis 만성 바이러스간염 바이러스간염 B18 US US20110124670A1 13/054011 20110124670 20090714 20110526 20110526 Novartis Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis The invention relates to the use of a pyrimidylaminobenzamides of formula I A61K31/506 A61K31/506|A61P43/00|A61K31/4184|A61P31/12|A61K31/4178|A61P11/00|A61K31/41|A61P1/16|A61K45/06 9 A61K31/506 A61K31/506|A61P11/00|A61P1/16 3
211725 Chronic viral hepatitis 만성 바이러스간염 바이러스간염 B18 US US20130267549A1 13/911127 20130267549 20130606 20131010 20131010 Novartis Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis The invention relates to the use of a pyrimidylaminobenzamides of formula I A61K31/506 A61K31/506|A61P1/16|A61K45/06|A61P43/00|A61K31/4184|A61P31/12|A61K31/4178|A61P11/00|A61K31/41 9 A61K31/506 A61K31/506|A61K31/41|A61K45/06 3
968869 Chronic hepatitis B 만성 B형간염 바이러스간염 B18.0-1 US US20220313690A1 17/627708 20220313690 20200717 20221006 20221006 Enyo Pharma SYNERGISTIC EFFECT OF EYP001 AND IFN FOR THE TREATMENT OF HBV INFECTION The present invention relates to a synergistic combination of EYP001 and interferon for the treatment of hepatitis B. A61K31/496 A61K31/496|A61K9/0019|A61P31/20|A61K47/60|A61K38/212 5 A61K31/496 A61K31/496|A61K38/21|A61P31/20|A61K47/60|A61K9/00 5
941134 Tinea unguium 손발톱백선 진균증 B35.1 US US00005744469B 08/756996 5744469 19961126 19980428 19980428 Eli Lilly and Company Method for treating dermatitis <p>The invention provides a method for treating fungal dermatitis comprising administering an effective amount of 2-Methyl-4-(4-methyl-1- piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine to a patient in need thereof.</p> A61K31/551 A61K31/551 1 A61K31/55 A61K31/55|A61K31/38 2
941075 Chronic viral hepatitis C 만성 C형간염 바이러스간염 B18.2 US US00009315545B2 14/680562 20150284429 9315545 20150407 20151008 20160419 20151008 Jolla Pharma Hepcidin mimetic peptides and uses thereof Compounds and methods are described herein that can be used to treat subjects for conditions related to hepcidin activity, such as but not limited diseases of iron metabolism, beta thalassemia, hemochromatosis, iron-loading anemias, alcoholic liver disease, or chronic hepatitis C. C07K7/06 C07K7/06|A61P1/16|A61P3/00|A61P7/00|A61P7/06|C07K7/02|A61K38/00 7 C07K7/06 C07K7/06|C07K7/02 2
941075 Chronic viral hepatitis C 만성 C형간염 바이러스간염 B18.2 US US20080207567A1 11/813252 20080207567 20060102 20080828 20080828 Brinkmann, Volker|Feutren, Gilles Treatment of Hcv Disorders S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV). A61K31/661 A61K31/661|A61P31/14|A61K31/381|A61P31/12|A61K31/137|A61P31/00|A61P1/16|A61P43/00|A61K31/397 9 A61K31/66 A61K31/66|A61K31/38|A61P31/00 3
941075 Chronic viral hepatitis C 만성 C형간염 바이러스간염 B18.2 US US20140018289A1 14/007499 20140018289 20120329 20140116 20140116 Novartis New treatments of Hepatitis C virus infection The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection. A61K38/12 A61K38/12|A61P31/14|A61K38/13|A61P1/16|A61K31/7056|A61K45/06|A61K31/395|A61K38/212|A61P43/00|A61K38/21 10 A61K38/13 A61K38/13|A61K45/06 2
941075 Chronic viral hepatitis C 만성 C형간염 바이러스간염 B18.2 US US20150139950A1 14/540469 20150139950 20141113 20150521 20150521 Novartis ALISPORIVIR TO TREAT HEPATITIS C VIRUS INFECTION The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection. A61K38/12 A61K38/12|A61P31/14|A61K38/13|A61P1/16|A61K31/7056|A61K45/06|A61K31/395|A61K38/212|A61P43/00|A61K38/21 10 A61K38/12 A61K38/12|A61K38/21|A61K31/7056|A61K45/06 4
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00005153318B 07/591916 5153318 19901002 19921006 19921006 Burroughs Wellcome 3'-Azido nucleoside compound <p>The present invention relates to 3'-azido purine nucleosides and their use in medical therapy, particularly for the treatment of human immunodeficiency virus and hepatitis B virus infections, to methods for their preparation and to compositions containing them.</p> C07H19/16 C07H19/16|A61P31/12 2 C07H19/00 C07H19/00|A61K31/7052|A61K31/708|C07H19/16|A61P31/12|A61K31/7042|A61K31/7076|A61K31/70 8
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00005196194B 06/679621 5196194 19841207 19930323 19930323 University of California Vaccines containing Hepatitis B S-protein <p>Recombinant full-length Hepatitis B surface antigen protein is disclosed. This protein is useful in vaccines for the prevention of Hepatitis B infection.</p> C07K14/005 C07K14/005|Y10S530/826|Y10S530/806|C12N2730/10122|A61K39/00 5 C12N15/51 C12N15/51|A61K39/00|C07K14/02 3
968871 hepatitis C C형간염 바이러스간염 B17.1|B18.2 US US00008030307B2 12/324048 20090180983 8030307 20081126 20090716 20111004 20090716 Enanta Pharmaceuticals Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: C07K5/0812 C07K5/0812|C07K5/06165|A61K38/00|A61P31/12 4 A61K38/12 A61K38/12|C07D225/04|C07K5/12|A61K31/407|A61K38/21|A61K31/517|A61K31/7052|A61P31/12|A61K31/47 9
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00005872206B 08/319376 5872206 19941006 19990216 19990216 Massachusetts General Hospital (MGH, Mass General) Compositions and methods for interfering wtih hepatitis B virus infection <p>The invention provides for compositions and methods for interfering with Hepatitis B viral infection that are based on the interaction of Hepatitis B virus X protein with a novel proteasome subunit.</p> C07K14/005 C07K14/005|C12N9/48|C12N2730/10122|C07K2319/00|A61K38/00 5 A61K38/00 A61K38/00|C07K2/00|C12N9/48|C12P21/04|C07K14/02 5
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00010745767B2 15/879921 20180195136 10745767 20180125 20180712 20200818 20180712 Cynosure|Faxitron Bioptics|Gen-Probe|Hologic Compositions and methods for detecting hepatitis B virus Compositions, methods and kits for detecting viral nucleic acids. Targets that can be detected in accordance with the invention include HBV and/or HIV-1 and/or HCV nucleic acids. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers that facilitate detection of very low levels of HBV nucleic acids. C12Q1/706 C12Q1/706|C12Q1/703 2 C12Q1/68 C12Q1/68|C12Q1/70 2
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00006583279B1 09/770532 6583279 20010126 20030624 20030624 Becton, Dickinson and Company (BD) Sequences and methods for detection of hepatitis B virus <p>Primers and probes derived from the HBV DNA polymerase gene which facilitate detection and/or quantification of all presently known genotypes of HBV. Disclosed sequences may be used in a variety of primer and probe constructs for detection of HBV nucleic acids.</p> C12Q1/706 C12Q1/706 1 C07H21/00 C07H21/00|C07H21/04|G01N33/576|C12Q1/68|C12P19/34|G01N33/566|C12Q1/70|C12N15/09|G01N33/53 9
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00007589077B2 10/477763 20040242533 7589077 20020517 20041202 20090915 20041202 Rakesh Kumar Antiviral nucleosides Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus. C07D239/54 C07D239/54|C07H19/06|C07H19/23|A61P31/22|A61P31/12|C07D403/04|C07D491/04 7 A61K31/7068 A61K31/7068|C07H19/06|C07H19/09|C07H19/073|A61K31/7072|C07H19/067|C07D403/04|A61K31/553|C07D239/54|A61K31/554|C07D498/18|C07D491/04|A61P31/12|C07H19/23 14
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00007473680B2 11/183205 20060030521 7473680 20050715 20060209 20090106 20060209 Novo Nordisk Remodeling and glycoconjugation of peptides The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide. C07K1/1077 C07K1/1077|A61K38/00|C07K14/505|C07K1/13|C07K9/00|C07K1/006 6 A61K38/00 A61K38/00|A61K38/14|C12P21/06|A61K38/16|C07K14/505|C07K1/00|C07K1/13|C07K1/107|C07K9/00 9
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00008227594B2 12/467939 20100130440 8227594 20090518 20100527 20120724 20100527 Rakesh Kumar Antiviral nucleosides Disclosed are nucleosides which are useful in diagnosing and treating viral infections, for example, infections caused by hepatitis B virus (HBV), and herpes viruses including Epstein Barr virus. C07D239/54 C07D239/54|C07H19/23|A61P31/22|A61P31/12|C07H19/06|C07D403/04|C07D491/04 7 A61K31/7068 A61K31/7068|A61K31/7072|C07H19/23|C07D498/18|A61K31/554|C07D239/54|C07D403/04|A61P31/12|A61K31/553|C07D491/04 10
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00008377994B2 12/299997 20090306224 8377994 20060510 20091210 20130219 20091210 Evonik Degussa Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions The use of Sch?lpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described. A61K9/1611 A61K9/1611|A61K9/1694 2 A61K47/00 A61K47/00|A61K31/19|A61K47/02|A61K9/20 4
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00008865881B2 13/400945 20120232133 8865881 20120221 20120913 20141021 20120913 California Institute of Technology (CALTECH) Delivery of proteins using adeno-associated virus (AAV) vectors Disclosed herein are compositions, systems and methods for delivery of proteins of interest using adeno-associated virus (AAV) vectors. C07K16/109 C07K16/109|C12N2750/14143|A61P31/20|C07K16/1045|A61P31/18|C12N7/00|C12N2750/14141|A61P31/12|A61P31/14 9 C07H21/04 C07H21/04|C12N15/63|C07K16/10|A61K48/00|A61P31/18|A61K31/713|C12N7/02|A61P31/12|C12N15/13|C12N15/861|A61P31/20 11
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00009205079B2 14/642393 20150174115 9205079 20150309 20150625 20151208 20150625 Novira Therapeutics Hepatitis B antiviral agents Provided herein are compounds useful for the treatment of HBV infection in man. A61K31/454 A61K31/454|A61K45/06|A61K31/404|C07D401/12|A61P31/12 5 A61K31/404 A61K31/404|A61K31/454|A61K45/06|C07D401/00|C07D401/12 5
968870 hepatitis B B형간염 바이러스간염 B16|B18.0-1 US US00009592282B2 12/374214 20100062028 9592282 20070716 20100311 20170314 20100311 GSK (GLaxoSmithKline) Biologicals Vaccines for malaria surface antigen S derived from Hepatitis B virus, or a fragment thereof. A61K39/015 A61K39/015|A61P1/16|A61P31/00|A61P33/06|C07K14/445|A61P33/02|A61K2039/6075|C07K2319/40|Y02A50/30 9 A61K39/015 A61K39/015|A61K39/00|C12N7/00|C07K14/445 4
연락처 및 데이터 관리
판매제공처 홈페이지 판매담당자 연락처 이메일
www.BLT.kr 특허법인BLT 02-514-0104 khpark@blt.kr
제약 및 취소환불 규정
제약 및 취소/환불 규정 안내
데이터 상품은 디지털화된 상품의 특성상 반품, 취소, 환불 되지 않으나 데이터의 심각한 오류, 상이한 데이터에 한하여 구매자가 요구하는 경우 환불을 진행할 수 있습니다.
상품 Q&A

※ 본인의 글만 수정이 가능하며, 타인의 글에 댓글을 남길 수 없습니다.
※ 댓글이 달린 글은 수정과 삭제가 불가능합니다.

등록된 글이 없습니다.